Author:
Lancet Jeffrey E,Uy Geoffrey L,Newell Laura F,Lin Tara L,Ritchie Ellen K,Stuart Robert K,Strickland Stephen A,Hogge Donna,Solomon Scott R,Bixby Dale L,Kolitz Jonathan E,Schiller Gary J,Wieduwilt Matthew J,Ryan Daniel H,Faderl Stefan,Cortes Jorge E
Funder
Jazz Pharmaceuticals Inc Ewing
Reference30 articles.
1. Outcome of patients aged 60–75 years with newly diagnosed secondary acute myeloid leukemia: a single-institution experience;Bertoli;Cancer Med,2019
2. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States;Medeiros;Ann Hematol,2015
3. Legg A, Ellison T, O'Connell M, Evans M. Analysis of treatments and outcomes for patients with de novo AML, therapy-related AML, and secondary AML (prior MDS and CMML) diagnosed in England between 2011–2016 using Hospital Episode Statistics. 25th Congress of the European Hematology Association (EHA). Online; June 11–14, 2020 (abstr 1929).
4. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study;Granfeldt Østgård;J Clin Oncol,2015
5. Age and acute myeloid leukemia;Appelbaum;Blood,2006
Cited by
87 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献